JPM26: What’s in a biopharma? CEO says Teva has the goods In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. | Under CEO Richard Francis, Teva has long bee...

#JPM26 #biopharma #Teva #TevaPharmaceuticals #RichardFrancis #innovativemedicines #generics #biopharmaidentity #PivottoGrowth #RoyaltyPharma #TEV408 #vitiligo #phase2bstudy #genericmedicines #schizophrenia #olanzapine #Uzedy #longactingmedication #biosimilars #biosimilarmarket
zurl.co/ErF5t

Guardant Health JPM26 Guardant Health presented at JP Morgan Healthcare 2026, and here we review their slide deck and give our highlights on the presentation.

Here are my #JPM26 highlights on Substack:
Guardant Health - albertvilella.substack.com/p/guardant-h...
Ginkgo Bioworks - albertvilella.substack.com/p/ginkgo-bio...
Recursion Pharma - albertvilella.substack.com/p/recursion-...
Twist Bio - albertvilella.substack.com/p/twist-bio-...

Next week, we’ll be at the 44th Annual J.P. Morgan Healthcare Conference. Tune in to the live audio webcast of our fireside chat on January 14, available here: https://bit.ly/3N8fbsi $ABBV #JPM26

#JPM26: Hua Medicine plots diabetes drug expansion in China and beyond Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua's drug for ...

Signal or noise? > #JPM26: Hua Medicine plots diabetes drug expansion in China
and beyond >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #productmarketing #pharmaceutical

GSK makes $2.2B deal for RAPT and its food allergy candidate GSK acquires RAPT Therapeutics for $2.2B, gaining ozureprubart antibody for food allergies. Deal marks GSK's first acquisition under new CEO Luke Miels and third biotech buyout of 2024.

🥣 #JPM26 left us hungry for a juicy M&A deal and we finally got one. GSK is moving on RAPT Therapeutics for $2.2B, the companies announced this morning.
endpoints.news/gsk-makes-2-...

A cup of Pliny the Elder on my way back after #JPM26

JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more  Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We won’t be sending newsletters on Monday, but we’ll be back in your inbox on Tuesday. The Endpoints News ... Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com

JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more 

Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We won’t be sending newsletters on Monday, but we’ll be back in your inbox on Tuesday. The Endpoints News ... Elevate your perspective with…

JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more  Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We won’t be sending newsletters on Monday, but we’ll be back in your inbox on Tuesday. The Endpoints News ... Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com

JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more 

Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We won’t be sending newsletters on Monday, but we’ll be back in your inbox on Tuesday. The Endpoints News ... Elevate your perspective with…

Belgian Immune System Drugmaker AgomAb Files for US IPO AgomAb Therapeutics NV filed for a initial public offering in the US to help fund trials of its drugs to treat immune and inflammation diseases.

European biotech Agomab files for a #Nasdaq IPO

Will we see a surge of news post #JPM26?

www.bloomberg.com/news/article...

Three women and one man, wearing pink to show support for women leaders in biotech.

A group photo of 800-1,000 people wearing pink to show support for women leaders in biotech at the JPM Healthcare Conference in 2026.

With #JPM26 wrapped up, we’re proud to share a Bonum tradition: the #BiotechCEOSisterhood annual #WearPink photo. John Mulligan (@jtm42.bsky.social) & Diane Hollenbaugh joined returnees Cindy Lai Yee & Neela Patel, and hundreds of attendees, to celebrate #WomenInBiotech leadership & industry equity.

SF Healthcare Week: Insitro CEO Daphne Koller on how AI is hitting “escape velocity” for finding causal targets for disease and speeding up drug development An early pioneer in the space, she describes the current state of AI in life sciences and the progress that Insitro is making.Daphne Kolher

insitro founder and CEO Daphne Koller sat down with BiotechTV during #JPM26. Daphne discusses how AI is helping insitro accelerate drug discovery and translate data into meaningful therapeutic insight. www.biotechtv.com/post/insitro...

Breaking down JPM 2026: the mood, the big interviews — and all the AI billboards STAT's Alex Hogan breaks down #JPM26 on STATus Report: the mood, the big interviews — and all the AI billboards.

STAT's @alexhogan.bsky.social breaks down #JPM26 on STATus Report: the mood, the big interviews — and all the AI billboards.
www.statnews.com/2026/01/15/j...

Generic GLP-1s are coming this year. The CEO in charge doesn't know what to expect As Sandoz prepares to launch what could be the world's first generic version of Novo's Ozempic in Canada and possibly Brazil in 2026, there are endless questions on how that market plays out.

#JPM26 takeaway? GLP-1s are hot. “Every time you mention GLP-1, I’m going to charge you $5. I’m going to donate it to, I don’t know, an injured Canadian seals fund or something like that," Sandoz CEO Richard Saynor said.
endpoints.news/jpm26-sandoz...

#BiotechHangout: Chris Garabedian, Mike Yee, Paul Matteis, Sam Fazeli will recap #JPM26, 2026 kickoff, VC investing, company news: $ALNY, $MRNA, deals: $ABBV, AI, regulatory: FDA updates, $ATRA, obesity: $LLY, $AMGN, $ABBV, $BMY, other data: $LXEO, $BMRN, $JNJ, $VRTX & $SION, $LLY: bit.ly/3Zg2m1H

It's a wrap.
#JPM26

It's a wrap.
#JPM26

Inside Fosun Pharma's ambition to be a global drug company Shanghai Fosun Pharmaceutical aims to build itself into a global drug innovator, co-president Xingli Wang told Endpoints News at the JP Morgan Healthcare Conference.

At #JPM26, Fosun Pharma laid out its ambition to become a global drugmaker, betting on in-house development and worldwide launches rather than just licensing assets to Big Pharma.

Will AI replace doctors? At our STAT@JPM event, Robert Nelsen told the audience, "Yes." #JPM26

The termination of $2B in grants by HHS Secretary Kennedy has now been reversed 24 hrs after they were announced during #JPM26 #JPM2026 yesterday. Bulwark confirmed Roll Call's reporting that HHS's decision has now been reversed h/t @samsteindc.bsky.social www.thebulwark.com/p/trump-take... #medsky

Dr. Oz & CDC's acting dir left the #JPM26 conf/SF for Minnesota. They posed for photos today in MN in between meetings h/t @ddiamond.bsky.social. CDC's acting dir is also Deputy Sec of HHS. He was appointed by RFK to replace Senate-confirmed Dr. Susan Monarez who left the CDC <month later #medsky

Daiichi's ADC optimism after safety flag $DSNKY $MRK #JPM26 firstwordpharma.com/story/7064917

How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism.

Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...

Loving, loving, LOVING this year’s #JPMPink, women leaders and allies in biotech/pharma wearing pink on conf. Tuesdays to support gender diversity and female leadership.

This year (1st) vs. last year (2nd). Hmmmm… wonder what happened since last Jan to bring out so much more support…? 🤔

#JPM26

STAT"s @matthewherper.bsky.social gives a run down on how #JPM26 has been thus far.
Check out all our coverage of the event here: www.statnews.com/topic/jpm/

What a turnout! Thanks to everyone who stopped by our #JPMHangout event – it was such a blast! Special shoutout to our Gold Badge sponsors CFGO, Syneos Health Communications, & Incubate Coalition – the night wouldn’t have been possible without them. Share photos in the comments! #JPM26

Drugmakers and investors want US reforms, not to slow down China Pfizer CEO Albert Bourla and others at JP Morgan Healthcare Conference advocate for US reforms to compete with China, rather than protectionist measures, amid increased US-China pharma deals.

At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development.

We hit the ground running in SF — reconnecting at T2B, gaining perspective at STAT, and gathering with the community at the WuXi Global Forum.

We also joined the Biotech CEO Sisterhood group photo — a meaningful moment highlighting the women leaders driving biotech forward.

More to come!

#JPM26

Permit and persist: Why women CEOs and allies flooded Union Square with pink during JPM - San Francisco Business Times Permit and persist: Why women biotech CEOs, allies flooded Union Square with pink #JPM26

Why hundreds of pink-clad execs flooded Union Square
#BiotechCEOSisterhood
#JPM26 share.google/mAHLVYQrXocN...

#JPM26 live blog day 3: Lilly CEO is unfazed by competitors JP Morgan Healthcare Conference: Lilly & Novo debate obesity pill requirements, Pfizer CEO warns of China competition, and Flagship's Afeyan disagrees with Nelsen on biotech intensity.

#JPM26 day 3: As the conference winds down, we’re tracking updates from WuXi AppTec and AbbVie — plus reactions from Lilly’s CEO, who says he’s unfazed by rising competition. Follow along for the latest from San Francisco.

Happening TODAY at #JPM2026!

Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).

#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD